AUSTRALIAN adults with moderate-to-severe ulcerative colitis will now have subsidised access to a new treatment option, known as Stelara (ustekinumab), via the PBS.
The initial dose of Stelara is given via intravenous infusion, while all maintenance doses are given by injection every eight weeks with the option of self-injection.
Stelara belongs to a drugs class called 'monoclonal antibodies' or 'biologics', which are special kinds of proteins that see and bind to other unique proteins in the body.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 23
